New targeted therapy for advanced prostate cancer shows anti-tumour activity in phase I clinical trials
Wednesday, November 7, 2012 - 22:00
in Health & Medicine
Few available treatment options exist once prostate cancer has spread to other parts of the body and has failed to respond to therapies that involve blocking the male hormone androgen. Patients with advanced, hormone-refractory prostate cancer usually die from the disease after 12 to 18 months, so new therapies are desperately needed. Researchers are reporting that a new drug that specifically targets a protein found on the surface of prostate cancer cells has performed well in a phase I clinical trial, and a phase II trial has started.